No Data
No Data
No Data
Ocumension Therapeutics Adjusts Share Capital
What You Can Learn From Ocumension Therapeutics' (HKG:1477) P/S
When you see that almost half of the companies in the Pharmaceuticals industry in Hong Kong have price-to-sales ratios (or "P/S") below 1.4x, Ocumension Therapeutics (HKG:1477) looks to be giving off
Ocumension Therapeutics Completes Phase III Trials for Postoperative Inflammation Drug
Ocumension Therapeutics' (HKG:1477) new drug for treating postoperative inflammation successfully achieved the expected results in a phase III clinical trial, according to a Monday filing with the Hon
Ocumension Therapeutics' Eye Drug Completes Clinical Trials, to Apply for NDA Soon
Ocumension Therapeutics (HKG:1477) said its new drug completed clinical phase III and will soon apply for a new drug registration, according to a Monday filing on the Hong Kong bourse. The drug, OT-70
No Data